AEON Biopharma Sets Annual Shareholder Meeting

AEON Biopharma (NYSE American: AEON) will hold its Annual Shareholder Meeting at 10:00 am PT on June 17, 2026 at the company offices, 5 Park Plaza, Suite 1750, Irvine, CA.

Rhea-AI Summary

AEON Biopharma (NYSE American: AEON) will hold its Annual Shareholder Meeting at 10:00 am PT on June 17, 2026 at the company offices, 5 Park Plaza, Suite 1750, Irvine, CA. Meeting materials are expected on or about April 29, 2026.

The company disclosed an audit going concern qualification for the fiscal year ended December 31, 2025, reflecting its liquidity position as of the audit date. The company expects cash and cash equivalents to fund operations into the third quarter of 2026.

Positive

• Annual meeting scheduled for June 17, 2026
• Meeting materials due on or about April 29, 2026
• Company disclosed cash runway into Q3 2026

Negative

• Auditor issued a going concern qualification for FY2025
• Liquidity limited to operations into third quarter of 2026

Argus Apr 27 session

-0.95% close to close Open Argus

Details

News Market Reaction – AEON

In the Apr 27 session, AEON declined 0.95%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the Annual Shareholder Meeting for June 17, 2026 and formally discloses that ...

Analysis

This announcement sets the Annual Shareholder Meeting for June 17, 2026 and formally discloses that the latest audit opinion includes a “going concern” qualification for the year ended December 31, 2025. Management expects cash to fund operations only into the third quarter of 2026, echoing liquidity concerns in recent SEC filings. Investors may watch upcoming financing actions, NYSE compliance milestones, and progress on the ABP-450 biosimilar program for further clarity.

Key Figures

Annual meeting time: 10:00 am PT Meeting date: June 17, 2026 Materials availability: On or about April 29, 2026 +2 more

Annual meeting time

10:00 am PT

Scheduled Annual Shareholder Meeting

Meeting date

June 17, 2026

Annual Shareholder Meeting date at company offices

Materials availability

On or about April 29, 2026

Expected date for shareholder meeting materials

Fiscal year end

December 31, 2025

Audited financials with going concern qualification

Cash runway

Into Q3 2026

Company expectation for funding operations

Historical Context

5 past events · Latest: Apr 03

5 events

1. Apr 03

   CFO inducement grants

   24h Move

   +2.4%

   CFO equity inducement awards tied partly to NYSE compliance milestones.

2. Apr 03

   NYSE notice deficit

   24h Move

   +2.4%

   Additional NYSE notice citing stockholders’ deficit and listing standard noncompliance.

3. Mar 30

   Full-year 2025 results

   24h Move

   -0.5%

   2025 financials with limited cash and funding visibility only into Q3 2026.

4. Mar 25

   FDA feedback BPD 2a

   24h Move

   -3.8%

   Constructive FDA BPD Type 2a feedback on ABP-450 analytical similarity strategy.

5. Mar 09

   CFO appointment

   24h Move

   +7.5%

   Appointment of experienced CFO to guide financing and regulatory milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

going concern qualification, nyse american company guide

2 terms

going concern qualification financial

"an audit report ... that included a going concern qualification, which is not uncommon"

An auditor's warning in a company’s financial report that there is serious doubt the business can keep operating for the foreseeable future (usually the next 12 months). It matters to investors because it flags a higher risk of bankruptcy, asset losses or major restructuring—similar to a mechanic saying a car may not make it through the season—so shareholders and lenders may reassess value, lending terms or whether to stay invested.

nyse american company guide regulatory

"As required by Section 610(b) of the NYSE American Company Guide, the Company also"

A handbook of rules and requirements that govern companies listed on the NYSE American market, covering eligibility to list, ongoing disclosure duties, corporate governance expectations, and trading practices. It matters to investors because it sets the minimum standards companies must meet to join and remain on that exchange — like a routine safety inspection that signals basic reliability and transparency — helping investors judge regulatory compliance, quality of public information, and potential risks to a stock’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 -

IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX^® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company’s offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614. Meeting materials are expected to be made available to shareholders on or about April 29, 2026.

NYSE Required Disclosure Regarding Audit Opinion

As required by Section 610(b) of the NYSE American Company Guide, the Company also hereby provides notice that its audited consolidated financial statements for the fiscal year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K, contained an audit report from its independent registered public accounting firm that included a going concern qualification, which is not uncommon for development-stage biopharmaceutical companies with ongoing capital requirements. This disclosure does not reflect any change to the Company’s previously filed financial statements or the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The going concern qualification reflects the Company’s liquidity position as of the audit date. The Company expects its cash and cash equivalents to fund operations into the third quarter of 2026.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX^®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau^®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of botulinum toxin products. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to continue to meet continued stock exchange listing standards; (ii) the Company’s planned annual shareholder meeting and any potential results thereof; (iii) the Company’s ability to obtain additional financing; (iv) the timing of making any Annual Shareholder Meeting materials available to shareholders; (v) the Company’s anticipated financial performance, including cash and cash equivalents; and (vi) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.

Contacts

Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com

Source: AEON Biopharma

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is AEON Biopharma's Annual Shareholder Meeting (AEON)?

The meeting is scheduled for 10:00 am PT on June 17, 2026. According to the company, it will be held at 5 Park Plaza, Suite 1750, Irvine, CA, and meeting materials are expected on or about April 29, 2026.

Where can AEON (AEON) shareholders access the meeting materials for the June 17, 2026 meeting?

Meeting materials are expected to be available on or about April 29, 2026. According to the company, materials will be provided to shareholders ahead of the June 17, 2026 Annual Shareholder Meeting for review.

What did AEON disclose about its audited financial statements for fiscal year 2025 (AEON)?

AEON disclosed an audit report containing a going concern qualification for the year ended December 31, 2025. According to the company, the qualification reflects the liquidity position as of the audit date and is not a change to filed statements.

How long does AEON expect its cash to fund operations (AEON)?

AEON expects its cash and cash equivalents to fund operations into the third quarter of 2026. According to the company, this estimate reflects available liquidity as of the audit date and the company's current operating plan.

Does the going concern qualification change AEON's filed Annual Report on Form 10-K (AEON)?

The disclosure does not change the company's previously filed financial statements or Annual Report on Form 10-K for 2025. According to the company, the going concern qualification relates to audit reporting and liquidity as of the audit date.